Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 155

Sort by

Sort Order Select

Journal Articles

Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

Guangrong Qin, PhD, Shmulevich Ilya, PhD, Taek-Kyun Kim, PhD, Bahar Tercan, PhD, Timothy J Martins, PhD, Jin Dai, PhD, Sylvia Chien, Andrew Carson, PhD, Bradley Patay, MD, Elihu H. Estey, MD, Lawrence A. Loeb, MD PhD, Raymond J. Monnat, MD PhD, Pamela S. Becker, MDPhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-142727

Published: 2020

Journal Articles

Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective Analysis

Kelsey-Leigh A Garcia, Philip A. Stevenson, MS, Sindhu Cherian, MD, Christen N. Martino, NP, Andrei R Shustov, MD, Pamela S. Becker, MDPhD, Mary-Beth M. Percival, MD, Vivian G. Oehler, MD, Anna B. Halpern, MD, Roland P Walter, MDPhD, Johnnie Orozco, MD, Colin D. Godwin, MDMPhil, Sioban Keel, MD, Elihu H. Estey, MD, Ryan D. Cassaday, MD

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-137780

Published: 2020

Journal Articles

Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia

Megan Othus, PhD, Guillermo Garcia-Manero, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-142551

Published: 2020

Journal Articles

Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia

Mallette M. Asmuth, MD, Anna B. Halpern, MD, Megan Othus, PhD, Emily Huebner, MS, Carole M. Shaw, BA, Kelda Gardner, PA-C, Elihu H. Estey, MD, Roland B. Walter, MDPhDMS, Colin D. Godwin, MDMPhil

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-142730

Published: 2020

Journal Articles

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban B. Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1317.

https://doi.org/10.1182/blood-2019-124586

Published: 2019

Journal Articles

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1323.

https://doi.org/10.1182/blood-2019-123605

Published: 2019

Journal Articles

Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Genevieve Alcorn, Mary-Elizabeth M. Percival, MD, Emily M Huebner, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Vivian G. Oehler, MD, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1364.

https://doi.org/10.1182/blood-2019-123542

Published: 2019

Journal Articles

Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count

Xueyan Chen, MD, Megan Othus, PhD, Brent L Wood, MD PhD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 2692.

https://doi.org/10.1182/blood-2019-124977

Published: 2019

Journal Articles

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

Colin D. Godwin, MDMPhil, Yi Zhou, MD PhD, Megan Othus, PhD, Carole M. Shaw, BA, Kelda M. Gardner, PA-C, Brent L Wood, MD PhD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 2729.

https://doi.org/10.1182/blood-2019-127128

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Kylee L Martens, MD, Parisa R Khalighi, BS, Shan Li, PharmD, Andrew A White, MD, Emily Silgard, MS, Deborah Frieze, PharmD, Elihu H. Estey, MD, David A. Garcia, MD, Sangeeta R Hingorani, MD MPH, Ang Li, MD

Blood (2019) 134 (Supplement_1): 4674.

https://doi.org/10.1182/blood-2019-124058

Published: 2019

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data

Megan Othus, PhD, Guillermo Garcia-Manero, MD, John E. Godwin, MD, James K. Weick, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 291.

https://doi.org/10.1182/blood-2019-127356

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Mary-Elizabeth M. Percival, MD, Hai-Lin Wang, MPH, Mei-Jie Zhang, PhD, Elihu H. Estey, MD, Mark Litzow, MD, Partow Kebriaei, MD, Marcos de Lima, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 4585.

https://doi.org/10.1182/blood-2019-123510

Published: 2019

Journal Articles

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

Kelda Gardner, PA-C, Megan Othus, PhD, Carole M. Shaw, BA, Pamela S. Becker, MD PhD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 5093.

https://doi.org/10.1182/blood-2019-130965

Published: 2019

Journal Articles

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Kelda Gardner, PA-C, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Anna B. Halpern, MD, Carole M. Shaw, BA, Jacob Appelbaum, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 5094.

https://doi.org/10.1182/blood-2019-131280

Published: 2019

Journal Articles

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Mary-Elizabeth M. Percival, MD, Megan Othus, PhD, Sarah Mirahsani, Kelda M. Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Pamela S. Becker, MD PhD, Mohamed L. Sorror, MD MSc, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 3824.

https://doi.org/10.1182/blood-2019-130834

Published: 2019

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

2 nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

Megan Othus, PhD, Elihu H. Estey, MD, Guillermo Garcia-Manero, MD, Brent Wood, MD PhD, Derek Stirewalt, MD, John Godwin, MD, James K. Weick, MD, Jeanne E. Anderson, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Roland B. Walter, MD PhD MS

Blood (2018) 132 (Supplement 1): 3978.

https://doi.org/10.1182/blood-2018-99-117525

Published: 2018

NARROW

Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective Analysis

Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia

Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

2 nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only